Delving into the Latest Updates on Adecto Pharmaceuticals, Inc. with Synapse

概览

疾病领域	数量

肿瘤	1

排名前五的药物类型	数量

单克隆抗体	1

排名前五的靶点	数量

ADAM8	1

关联

3

项与 Adecto Pharmaceuticals, Inc. 相关的药物

MAB-1031

靶点

ADAM8

作用机制

ADAM8 antagonists

在研机构

Adecto Pharmaceuticals, Inc.初创企业

原研机构

Tufts University

在研适应症

乳腺癌

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

ADP13 (Adecto Pharmaceuticals)

靶点

ADAM8

作用机制

ADAM8 antagonists

在研机构

Institut de Cancérologie de l'Ouest (ICO) [+1]

原研机构

Adecto Pharmaceuticals, Inc.初创企业

在研适应症

三阴性乳腺癌

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

ADP2 (Adecto Pharmaceuticals)

靶点-

作用机制-

在研机构-

原研机构

Adecto Pharmaceuticals, Inc.初创企业

在研适应症-

非在研适应症

乳腺癌

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 Adecto Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Adecto Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 Adecto Pharmaceuticals, Inc. 相关的文献（医药）

Cancer Cell International

ADAM8 is expressed widely in breast cancer and predicts poor outcome in hormone receptor positive, HER-2 negative patients

Article

作者: Sonenshein, Gail E ; Mineva, Nora D ; Michael, Steven J ; Pianetti, Stefania ; Althouse, Sandra ; Cao, Sha ; Chen, Hannah H ; Miller, Kathy D

AbstractBackgroundBreast malignancies are the predominant cancer-related cause of death in women. New methods of diagnosis, prognosis and treatment are necessary. Previously, we identified the breast cancer cell surface protein ADAM8 as a marker of poor survival, and a driver of Triple-Negative Breast Cancer (TNBC) growth and spread. Immunohistochemistry (IHC) with a research-only anti-ADAM8 antibody revealed 34.0% of TNBCs (17/50) expressed ADAM8. To identify those patients who could benefit from future ADAM8-based interventions, new clinical tests are needed. Here, we report on the preclinical development of a highly specific IHC assay for detection of ADAM8-positive breast tumors.MethodsFormalin-fixed paraffin-embedded sections of ADAM8-positive breast cell lines and patient-derived xenograft tumors were used in IHC to identify a lead antibody, appropriate staining conditions and controls. Patient breast cancer samples (n = 490) were used to validate the assay. Cox proportional hazards models assessed association between survival and ADAM8 expression.ResultsADAM8 staining conditions were optimized, a lead anti-human ADAM8 monoclonal IHC antibody (ADP2) identified, and a breast staining/scoring control cell line microarray (CCM) generated expressing a range of ADAM8 levels. Assay specificity, reproducibility, and appropriateness of the CCM for scoring tumor samples were demonstrated. Consistent with earlier findings, 36.1% (22/61) of patient TNBCs expressed ADAM8. Overall, 33.9% (166/490) of the breast cancer population was ADAM8-positive, including Hormone Receptor (HR) and Human Epidermal Growth Factor Receptor-2 (HER2) positive cancers, which were tested for the first time. For the most prevalent HR-positive/HER2-negative subtype, high ADAM8 expression identified patients at risk of poor survival.ConclusionsOur studies show ADAM8 is widely expressed in breast cancer and provide support for both a diagnostic and prognostic value of the ADP2 IHC assay. As ADAM8 has been implicated in multiple solid malignancies, continued development of this assay may have broad impact on cancer management.

100 项与 Adecto Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Adecto Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

1

2

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

MAB-1031 ( ADAM8 )	乳腺癌更多	临床前
ADP13 (Adecto Pharmaceuticals) ( ADAM8 )	乳腺癌更多	无进展
ADP2 (Adecto Pharmaceuticals)	乳腺癌更多	无进展